Tag: years

SAN DIEGO, CA, Aug. 15, 2025 (GLOBE NEWSWIRE) -- RYVYL Inc. (NASDAQ: RVYL) ("RYVYL” or the "Company") today announced the retirement of Chairman and Co-founder Ben Errez, effective August 31, 2025. RYVYL is repositioning its business to focus on crypto treasury management, beginning with a core strategy centered on building a crypto treasury to support long-term growth.

Public curiosity around nerve health is rising in 2025, with searches, podcasts, and social platforms highlighting natural approaches. Nerve Soothe enters this conversation with a formula designed around ingredient transparency, plant-based extracts, and consumer-driven expectations for wellness support.

In today's rapidly evolving digital asset era, DIFD AUTO is leading the global cryptocurrency car buying revolution.

Bagsværd, Denmark, 15 August 2025 – Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved an additional indication for Wegovy^® (semaglutide 2.4 mg) based on a supplemental New Drug Application (sNDA) for treatment of noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) in adults with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis), in combination with a reduced calorie diet and increased physical activity.

   
- Successfully initiated enrollment in advanced Phase 2 ovarian cancer trial

SINGAPORE, Aug. 15, 2025 (GLOBE NEWSWIRE) -- Ebang International Holdings Inc. (Nasdaq: EBON, the “Company,” “we,” “us” or “our”), today announced its unaudited financial results for the first six months of fiscal year 2025.

BOSTON, Aug. 15, 2025 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that, effective on August 12, 2025, the company issued inducement awards to Adam Craig, M.D., John Volpone and David Kirske under the X4 Pharmaceuticals, Inc. 2019 Inducement Equity Incentive Plan (the “2019 Inducement Plan”), consisting of (i) options to purchase an aggregate of 4,250,718 shares of X4’s common stock granted to Dr. Craig, (ii) options to purchase an aggregate of 4,250,718 shares of X4’s common stock granted to Mr. Volpone and (iii) options to purchase an aggregate of 2,833,812 shares of X4’s common stock granted to Mr. Kirske. In addition, effective on August 14, 2025, the company issued additional inducement awards to Dr. Craig, Mr. Volpone and Mr. Kirske under the 2019 Inducement Plan, consisting of (i) options to purchase an aggregate of 529,201 shares of X4’s common stock granted to Dr. Craig, (ii) options to purchase an aggregate of 529,201 shares of X4’s common stock granted to Mr. Volpone and (iii) options to purchase an aggregate of 352,800 shares of X4’s common stock granted to Mr. Kirske.

Tonmya is the first FDA-approved therapy for the treatment of fibromyalgia in over 15 years